TELA Bio Business Summary

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company that generates revenue through the direct sale of its proprietary reinforced tissue matrices designed for complex soft-tissue reconstruction. The company’s business model is centered on two primary segments: the OviTex portfolio, which addresses ventral, inguinal, and hiatal hernia repairs, and the OviTex PRS portfolio, specifically engineered for plastic and reconstructive surgery. TELA Bio differentiates itself in the market by utilizing ovine-derived matrices interwoven with minimal polymer to promote natural healing and minimize long-term exposure to permanent synthetic materials, a strategy furthered by its recent expansion into robotic and laparoscopic surgical markets. Within the competitive landscape, TELA Bio contends with medical device players such as Apyx Medical, Treace Medical Concepts, and Mimedx Group, positioning itself as a high-growth specialist in bio-resorbable solutions that prioritize anatomical restoration. TELA Bio was co-founded by Antony Koblish and Dr. Maarten Persenaire, with Koblish currently serving as CEO and Director, leveraging his previous success as CEO of Orthovita (acquired by Stryker). The executive leadership team includes President Jeffrey Blizard, who joined in June 2025 to drive commercial scaling, Roberto Cuca as COO and CFO, and Paul Talmo as Chief Technology Officer. The company’s strategic oversight is provided by a board of directors chaired by Doug Evans and featuring recent appointees such as Bill Plovanic and Betty Jo Rocchio. TELA Bio has secured significant institutional backing from investors including ProMedica and Checkmate Capital, and recently strengthened its financial runway through an upsized $70 million credit facility with Perceptive Advisors to fund its 2026 growth initiatives and international expansion.